Serum protein-based nanoparticles for cancer diagnosis and treatment.

Abstract

Serum protein as naturally essential biomacromolecules has recently emerged as a versatile carrier for diagnostic and therapeutic drug delivery for cancer nanomedicine with superior biocompatibility, improved pharmacokinetics and enhanced targeting capacity. A variety of serum proteins have been utilized for drug delivery, mainly including albumin, ferritin/apoferritin, transferrin, low-density lipoprotein, high-density lipoprotein and hemoglobin. As evidenced by the success of paclitaxel-bound albumin nanoparticles (AbraxaneTM), serum protein-based nanoparticles have gained attractive attentions for precise biological design and potential clinical application. In this review, we summarize the general design strategies, targeting mechanisms and recent development of serum protein-based nanoparticles in the field of cancer nanomedicine. Moreover, we also concisely specify the current challenges to be addressed for a bright future of serum protein-based nanomedicines.

• Authors: Haroon Iqbal, Tao Yang, Ting Li, Miya Zhang, Hengte Ke, Dawei Ding, Yibin Deng, Huabing Chen
• Journal: Journal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 329 Pg. 997-1022 (01 10 2021) ISSN: 1873-4995 [Electronic] Netherlands
• PMID: 33091526 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020. Published by Elsevier B.V.

Chemical References

• Transferrin

Topics

• Drug Delivery Systems
• Humans
• Nanomedicine
• Nanoparticles
• Neoplasms (diagnosis, drug therapy)
• Transferrin